Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.

CompletedOBSERVATIONAL

Enrollment

156

Participants

Timeline

Start Date

September 5, 2017

Primary Completion Date

October 28, 2020

Study Completion Date

October 28, 2020

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

Osimertinib

80mg oral daily

Trial Locations (4)

Pamela Youde Nethersole Eastern Hospital, Hong Kong

Prince of wales hospital, Hong Kong

Queen Mary Hospital, Hong Kong

Tuen Mun Hospital, Hong Kong